Genomic assays have transformed decision-making in early-stage breast cancer by focusing on tumor biology rather than traditional clinicopathologic factors.
2
The MINDACT trial showed that HR+/HER2- patients with low genomic risk do not benefit from adjuvant chemotherapy and can achieve excellent outcomes with endocrine therapy.
3
Genomic profiling is increasingly used to tailor neoadjuvant therapy regimens, predicting treatment response and informing surgical planning for HR+/HER2- breast cancers.
4
Insights from genomic testing can influence surgical decisions, determining the appropriateness of breast-conserving surgery versus mastectomy based on tumor biology.
5
Genomic risk stratification tools help clinicians avoid overtreatment by identifying patients with low-risk profiles who may not benefit from intensive therapies.
